A team of researchers from the National University of Singapore (NUS), in collaboration with doctors from the National University of Cancer Society, Singapore (NCIS) which is part of the National University Health Center (NUHS), report interesting results in the use of CURATE.AI. , Artificial intelligence (AI) technology that allows doctors to make the best doses of chemotherapy for patients.
Based on the pilot clinical test — called PRECISE.CURATE — which includes 10 patients In Singapore those diagnosed with malignant tumors and most common cancers, doctors accept almost 97% of the doses recommended by CURATE.AI, with some patients being receive improved doses that are almost 20% less than average. These first results are an interesting step for the possibility of truly specializing in oncology, where drugs strength can be adjusted during treatment.
Developed by Professor Dean Ho and his team, CURATE.AI is an optimization platform that enhances the patient’s clinical data, which includes the type of treatment, the number of medications and the cancer patients, to create digital data for a single user. it to isolate the optimal dose during the course of chemotherapy treatment.
“Chemotherapy is often given at very specific prescriptions, depending on the patient’s specific parameters. However, these toxic control measures may result in a better response to treatment. The use of CURATE.AI, which “We hope to help doctors quickly. Find the best vaccines that are tailored to each patient at different stages of the treatment cycle. The ultimate goal is to improve the patient and the outcome of treatment,” said Professor Ho, who is leading Department of Molecular Engineering under the NUS College of Engineering and Engineering. Health N.1 (N.1) at NUS.
He added, “The goal of CURATE.AI is to have more responses to treatment, and to find the right doses for patients that can improve the quality and / or prolong the time the patient responds to treatment. For some patients, “These doses may be lower than normal doses.”
“An important aspect of the use of AI in medicine is the direct involvement of hospital physicians in building one-on-one data. Pilot testing represents an exciting step to integrate CURATE.AI into the clinical practice of The key choice in the treatment of cancerous tumors.The key. of CURATE.AI is to provide a truly unique treatment for patients while allowing physicians to identify the best dose for each patient, without increasing their performance.Raghav Sundar, Senior Researcher of PRECISE.CURATE clinical trials, and consultant in the Department of Hematology-Oncology, NCIS.
How does CURATE.AI work?
CURATE.AI uses a compact database to adjust the number of medications for each patient using his or her own clinical data. Each patient is given a variety of medications and his / her response to these types of doses is measured. This data, along with other relevant clinical data, is used to build digital profiles for each patient. By linking the number of doses to the quality of treatment and safety, CURATE.AI selects the right doses to maximize treatment outcomes for each digital profile. During treatment, sepsis may occur over time.
During the pilot test, conducted from August 2020 to April 2022 at the National University Hospital, doctors were allowed to accept or reject CURATE.AI dose recommendations based on clinical judgment.
“The pilot test results are very encouraging. We have noticed a reduction in chemotherapy reductions by almost 20%, and 96.7% of CURATE.AI dose recommendations have been approved by doctors,” said Dr. Agata BIasiak. , co-author and co-author of the study.
“Other research results show that 80% of patients follow the recommended steps, and 100% agree to provide dosing recommendations within the required time. These initial results are a positive step forward in the implementation of CURATE.AI in the ground. medicine“said Dr. Blasiak, who is also from CDE, WisDM and N.1 at NUS.
As a possible study and intervention using an AI-based system for human treatment, the pilot test results were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Conference. ASCO is a large association of health professionals who care for cancer patients, and the conference will showcase the latest developments. cancer research.
“On a global scale, obtaining a clinical clinical trial of a technology from the Department of Biomedical Engineering approved for presentation at the ASCO annual conference is extremely difficult. This reflects the real world and the impact of the patient achieved through innovation involving the Engineering, Medicine. and many other fields required to bring out the changing culture, ”said Professor Ho.
Following this initial advancement to integrate CURATE.AI in the clinical practice of bone marrow transplantation into advanced tumor treatment, the NUS team will proceed to a larger, randomized trial to further improve the performance of the enhancement platform.
The research team will also conduct clinical trials involving patients diagnosed with certain types of cancer, such as multiple myeloma, and diseases such as high blood pressure, among others. Interestingly, the team is also launching a near-term trial to improve its unique cancer-fighting immunity.
Singapore National University
hintThe AI platform allows physicians to upgrade to a specific amount of chemotherapy (2022, June 13) which was retrieved June 13, 2022 from https://medicalxpress.com/news/2022-06-ai-platform-enables-doctors-optimize. html
This document is copyrighted. Apart from any genuine transaction for the purpose of personal analysis or investigation, no part may be reproduced without our written permission. Content is provided for informational purposes only.
AI platform enables doctors to optimize personalized chemotherapy dose Source link AI platform enables doctors to optimize personalized chemotherapy dose